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Abstract
Objective To investigate the planning of subgroup analyses in protocols
of randomised controlled trials and the agreement with corresponding
full journal publications.
DesignCohort of protocols of randomised controlled trial and subsequent
full journal publications.
Setting Six research ethics committees in Switzerland, Germany, and
Canada.
Data sources 894 protocols of randomised controlled trial involving
patients approved by participating research ethics committees between
2000 and 2003 and 515 subsequent full journal publications.
Results Of 894 protocols of randomised controlled trials, 252 (28.2%)
included one or more planned subgroup analyses. Of those, 17 (6.7%)
provided a clear hypothesis for at least one subgroup analysis, 10 (4.0%)
anticipated the direction of a subgroup effect, and 87 (34.5%) planned
a statistical test for interaction. Industry sponsored trials more often
planned subgroup analyses compared with investigator sponsored trials
(195/551 (35.4%) v 57/343 (16.6%), P<0.001). Of 515 identified journal
publications, 246 (47.8%) reported at least one subgroup analysis. In
81 (32.9%) of the 246 publications reporting subgroup analyses, authors
stated that subgroup analyses were prespecified, but this was not
supported by 28 (34.6%) corresponding protocols. In 86 publications,
authors claimed a subgroup effect, but only 36 (41.9%) corresponding
protocols reported a planned subgroup analysis.
Conclusions Subgroup analyses are insufficiently described in the
protocols of randomised controlled trials submitted to research ethics
committees, and investigators rarely specify the anticipated direction of
subgroup effects. More than one third of statements in publications of
randomised controlled trials about subgroup prespecification had no
documentation in the corresponding protocols. Definitive judgments
regarding credibility of claimed subgroup effects are not possible without
access to protocols and analysis plans of randomised controlled trials.
Introduction
The primary goal of a randomised controlled trial is to determine
the benefits and harms of an intervention. However, trial
populations are typically heterogeneous for individual patient
characteristics such as age, sex, disease severity, or comorbidity.
The question therefore arises as to whether effects of an
intervention vary across these patient characteristics.
Randomised controlled trials commonly report exploration of
such possible subgroup effects1-5 and, if conducted appropriately,
such exploration can lead to more targeted clinical
recommendations, better informed clinical decision making,
and improved patient care.6 7 More often, their results are
misleading and can have detrimental consequences.8 9
Because subgroup analyses may be either informative or
misleading, healthcare providers and policymakers need criteria
to differentiate credible from spurious subgroup effects.8 10
Clinical epidemiologists have suggested criteria8-12 that allow
readers to gauge the likelihood that a subgroup effect is real, on
a continuum from highly plausible to extremely unlikely.13 All
available criteria include the prespecification of subgroup
analyses; some additionally include the anticipated direction of
the subgroup effect and the use of a statistical test tackling the
likelihood that apparent subgroup effects may be explained by
chance.8-13
Judging the credibility of a reported subgroup effect relies on
the information provided in published articles, because trial
protocols are usually not freely accessible. Little is known about
the planning of subgroup analyses in trial protocols and the
extent to which they are reported in subsequent publications,
and, in particular, which claims of prespecification correspond
to these descriptions.14 15 Pioneer work by Chan and colleagues16
suggested large discrepancies between protocols and
publications, but their sample was limited to 70 protocols of
randomised controlled trials from a single centre.
We investigated subgroup planning and reporting based on
protocols of randomised controlled trials from six international
centres and the corresponding publications. We focused
specifically on the agreement between statements about
subgroup prespecification in the publication and corresponding
statements in the protocols.
Methods
Study design
We used protocols of randomised controlled trials and
corresponding publications included in a retrospective cohort
study; the rationale and design have been described elsewhere.17
In short, the study examined protocols approved between 2000
and 2003 by six research ethics committees in Switzerland
(Basel, Lucerne, Zurich, and Lausanne), Germany (Freiburg),
and Canada (Hamilton). We focused on protocols that had been
approved 10 or more years ago to ensure that the number of
ongoing randomised controlled trials would be limited.18
Eligibility criteria for protocols and
subsequent publications
In the present study, we included protocols regardless of
publication status. We excluded those of trials that compared
different doses or routes of administering the same drug (early
dose finding studies), enrolled only healthy volunteers, were
never started, or were still ongoing as of April 2013. We
included only full (peer reviewed) journal publications from
corresponding protocols of randomised controlled trials; we
excluded research letters, letters to the editor, or conference
abstracts.
Definitions
We defined a subgroup as a subset of all trial participants with
distinct characteristics at randomisation (for example, age, sex,
stage of disease). We defined a subgroup analysis as an analysis
that explored whether intervention effects (experimental versus
control) differed according to these characteristics. For
protocols, we considered a subgroup analysis as planned if at
least one of the following was reported: any statement in the
protocol analogous to the definition above (for example,
“intervention effects will be investigated according to patient
baseline characteristics”); a stratified analysis (for example,
“patients will be stratified according to sex and analysed
separately”); a test for interaction (that is, interaction between
intervention and patient characteristic); or an investigation of
effect modifying factors. For publications, we considered a
subgroup analysis as reported if the article included at least one
of the following: an effect estimate and an associated confidence
interval or a P value for one or more subgroups; a difference
between effect estimates of different patient subgroups;
investigation of potential effect modifiers, or the results from
Extra material supplied by the authors (see http://www.bmj.com/content/349/bmj.g4539?tab=related#datasupp)
Table showing characteristics of trials as reported in published journal articles
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a test for interaction; or an explicit statement that a subgroup
analysis had been undertaken. We assessed protocols for
industry sponsorship or investigator sponsorship using the
following criteria: the protocol clearly named the sponsor,
displayed a company or institution logo prominently, mentioned
affiliations of authors of the protocol, included statements about
data ownership or publication rights, or included statements
about full funding by industry or public funding agencies.18
Data extraction process and search for
publications
Twelve investigators trained in clinical research methodology
independently extracted data from eligible trial protocols and
correspondence between the research ethics committees and the
local investigators. Thirty per cent of the extractions were done
in duplicate as an initial calibration process to maximise the
consistency of data extraction across reviewers. If the files of
the ethics committee provided no information about the
publication status of a trial, we conducted comprehensive
searches of electronic databases to find any associated
publications; previous publications present details of the
searches and data extraction process.17 18 When randomised
controlled trials that mentioned any prespecified subgroup
analyses in their publications did not mention any subgroup
analyses in corresponding protocols, we searched for additional
versions of the protocol published in journals, any available
analysis plans (from journals, filed documents at research ethics
committees, or websites), and information published in trial
registries (clinicaltrials.gov, WHO International Clinical Trials
Registry Platform). Twenty two investigators trained in clinical
research methodology extracted data from all corresponding
publications, independently and in duplicate; disagreements
were resolved by consensus or by third party adjudication.
Protocols and corresponding publications were not extracted
by the same person.
Information collected about subgroup
analyses
We recorded the number of subgroup analyses planned in
protocols and reported in publications. We asked the several
questions, guided by criteria for the credibility of subgroup
analyses.19 For protocols: any subgroup analyses mentioned? If
yes: Any clear hypothesis for the planned subgroup analyses
mentioned? Any anticipated direction of a subgroup effect
mentioned? Any test for interaction mentioned? How many
subgroup analyses were planned?
For publications: does the publication report any subgroup
analysis? If yes: Does the publication report that subgroup
analyses were prespecified? Does the publication report that
subgroup analyses were done post hoc? Does the publication
provide a rationale for any subgroup analysis? Does the
publication report an anticipated direction of any subgroup
effect? Does the publication report any separate power
calculation for subgroup analyses? Does the publication report
any test for interaction? How many subgroup analyses are
reported? Does the publication report any claim about a
subgroup effect? We considered a subgroup effect as claimed
if the investigators explicitly stated in the abstract or
discussion/conclusion that the effect of an intervention was
different between subgroups or a clear benefit or harmwas seen
in one or more subgroups.
Statistical analysis
For binary data we summarised results as frequencies and
proportions and for continuous data as medians and interquartile
ranges. We considered three analysis sets: a dataset based on
all protocols (protocol set), a dataset based on corresponding
publications (publication set), and a dataset of publications and
matched corresponding protocols (publication-protocol set).
We prespecified stratification of our descriptive analyses by
sponsorship and hypothesised, based on results reported by Sun
and colleagues, that industry sponsored trials more often planned
subgroup analyses.1We examined the difference between these
proportions using the χ2 test. We used the statistical programmes
R version 2.15.3 (www.r-project.org) and STATA version 13.0
(Stata, College Station, TX, USA) for our analyses.
Results
Planning of subgroup analyses—the protocol
set
Of 894 eligible protocols of randomised controlled trials
involving patients (figure⇓), 252 (28.2%) planned at least one
subgroup analysis. Those trials planning subgroup analysis had
on average a larger sample size, were more often multicentre
trials, and were from the specialty of cardiovascular medicine
(table 1⇓). Industry sponsored trials more often planned
subgroup analyses than investigator sponsored trials (195/551
(35.4%) v 57/343 (16.6%), P <0.001). Of the 252 protocols
planning at least one subgroup analysis, 17 (6.7%) provided a
hypothesis and 10 (4.0%) provided an anticipated direction of
a potential subgroup effect (table 2⇓).
Reporting of subgroup analyses—the
publication set
For 515 protocols we identified corresponding full journal
publications (publication set, figure). Of those, 246 (47.8%)
publications reported subgroup analyses. These trials were, on
average, larger andmore often published in high impact journals
than published randomised controlled trials without subgroup
reporting (see supplementary table 1). Table 3⇓ summarises the
reporting of subgroup credibility criteria and characteristics of
subgroup analyses in these full journal publications. Similar to
the protocol set, subgroup hypotheses or anticipated directions
of subgroup effects were rarely provided. Of 86 publications
claiming a subgroup effect, 39 (45.3%) reported the use of an
interaction test, 9 (10.5%) provided a subgroup hypothesis, and
5 (5.8%) provided an anticipated direction of effect.
Agreement between subgroup reporting in
publications and corresponding
protocols—the publication-protocol set
Of 515 publications of randomised controlled trials, 132 (25.6%)
reported the conduct of subgroup analyses that were not
mentioned in the corresponding protocols; 64 (12.4%)
publications did not report subgroup analyses that were planned
in the corresponding protocols.
Of those 246 publications that reported subgroup analyses,
overall 114 (46.3%) corresponding protocols planned at least
one subgroup analysis (for industry sponsored trials 86/160
(53.8%), for investigator sponsored trials 28/86 (32.6%)). In
those 114 trials, the reported number of subgroup analyses
matched the planned number in the protocol in 11 (9.6%)
instances. Table 4⇓ summarises the agreements of subgroup
credibility criteria for those 246 trials reporting at least one
subgroup analysis. In 81 of 246 (32.9%) publications reporting
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subgroups, authors stated for at least one of their reported
subgroup analyses that it was prespecified, but 28 (34.6%)
corresponding protocols had not mentioned any planned
subgroup analysis. For 12 of these 28 randomised controlled
trials, the authors mentioned a separate analysis plan in the
publication or the protocol without mentioning subgroup
analyses. However, these analysis plans were not made available
to readers. We found registered information for 9 (32.1%) of
the 28 randomised controlled trials but without any evidence
of planned subgroup analyses. Of the 86 publications claiming
a subgroup effect, 36 (41.8%) corresponding protocols reported
a planned subgroup analysis.
Discussion
Our study provides empirical evidence documenting the
planning and reporting of subgroup analyses in a sample of 894
randomised controlled trials involving patients, which were
approved by six research ethics committees in three countries.
About half of the published trials reported the conduct of
subgroup analyses, of which only 46% had mentioned any
planned subgroup analyses in the corresponding protocols.
Industry sponsored randomised controlled trials planned
subgroup analyses more often than investigator sponsored trials,
but still only half of industry sponsored trials reporting results
for subgroups explicitly stated such planned analyses in the
protocol. In trials with subgroup analyses mentioned in both
the protocol and the publication, the number of subgroup
analyses reported in publications matched the number in
protocols in only 10%. Investigators rarely provided a rationale
for or indicated the anticipated direction of potential subgroup
effects in either protocols or reports of randomised controlled
trials. Of the journal publications stating that at least one
subgroup analysis was preplanned, a third failed to mention any
subgroup analysis in the corresponding protocol.
Strengths and limitations of this study
The data for the present study were collected as part of a large
international cohort involving six research ethics committees
that allowed full access to trial protocols and filed
correspondence.17 18As outlined previously,20 unrestricted access
is absolutely necessary (but not always granted) to maintain
scientific rigor: asking trialists and sponsors for permission to
access their protocols would very likely introduce bias, because
those with substandard reporting practices may be less likely
to allow additional scrutiny. As further strengths we involved
only trained methodologists in data abstraction and performed
all data extractions from identified publications independently
and in duplicate. Finally, our sample included randomised
controlled trials from various disciplines of clinical medicine,
thus enhancing generalisability of our results.
Our study has limitations. Firstly, we did not have access to
statistical analysis plans that may have had prespecified
subgroup analyses not mentioned in the protocol. However, we
exhaustively checked all available evidence (published
protocols, trial websites, filed documents at research ethics
committees, trial registries) for prespecification of subgroup
analyses. Nevertheless, our results fail to take into account
changes in the protocol that occurred before examination of the
data and that were not recorded in any of the above documents.
Secondly, we did not systematically extract information from
protocols about separate power calculations for subgroup
analysis. However, since only 4% of protocols that planned
subgroup analysis provided an anticipated direction of a
subgroup effect, appropriate power calculations (additionally
including an estimate for the magnitude of the subgroup effect)
were likely to be even less common. Only 2.4% of publications
that mentioned a subgroup analysis reported a corresponding
power calculation. Thirdly, we used a convenience sample of
six research ethics committees, which were, to our knowledge,
not in any way particular. Still, we cannot say whether they are
representative of other research ethics committees in their own
or other countries. Fourthly, owing to limited resources we used
single data extraction for 70% of protocols, thereby potentially
increasing errors in extraction. However, we used pre-piloted
extraction forms with detailed written instructions, conducted
formal calibration exercises with all data extractors, and checked
extractions from a random sample of protocols at several points
during the process. Agreement was good, with no more than
two discrepancies in 30 extracted key variables.18 Fifthly, instead
of a formal protocol for the current substudy, we previously
published a protocol only of the overall project, mentioning this
study without details.17 Therefore we limited hypothesis testing
in this study to one prespecified subgroup analysis and wemake
our data extraction forms reflecting all collected variables
available to readers on request. Sixthly, included protocols were
approved 10-13 years ago; the planning of subgroup analyses
in protocols may have improved since that time.
Comparison with other studies
In an earlier systematic review of 469 randomised controlled
trials19 we found that 44% of full text publications reported
subgroup analyses, which is consistent with our present finding
of 48%. In the previous study, we found that most claimed
subgroup effects in randomised controlled trials had low
credibility and prespecificationwas seldom reported. The present
study not only confirms this finding, but reveals that, often, the
claim of prespecification of subgroups in publications is not
supported by the corresponding protocols.
Many previous empirical studies mentioned that justification
of subgroup analysis and the statistical methods used were rarely
reported.2-22Of those, only some smaller studies compared grant
applications22 or protocols of randomised controlled trials14 16
with publications for information about subgroup analyses and
identified considerable discrepancies: Boonacker and colleagues
noted that only 11 of 47 (23%) grant proposals for randomised
controlled trials were in agreement with publications22; Chan
and colleagues found that 25 of 70 (36%) randomised controlled
trials reported subgroup analyses in the protocol or in the
publication and that there were discrepancies between the two
documents for all 25 randomised controlled trials16; and
Al-Marzouki and colleagues documented that only 8 of 19 (42%)
protocols of randomised controlled trials not mentioning
subgroup analyses and 7 of 18 (39%) protocols planning
subgroup analyses were consistent with corresponding
publications.14 In our sample, numbers of subgroup analyses in
protocols and publications were identical in less than 5%
(11/246) of randomised controlled trials reporting subgroups.
Only Chan and colleagues examined whether reported
prespecification of subgroup analyses in publications (7/20,
35%) was supported by planned subgroup analyses in protocols.
Four of 7 (57%) randomised controlled trials with reported
prespecifications lacked evidence of prespecification in the
corresponding protocols.16
Implications for reporting and interpreting
subgroup analyses
Current recommendations aim to help readers when judging the
credibility of subgroup analyses based on information provided
in the publication.9 13 Empirical evidence from comparisons of
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protocols of randomised controlled trials and publications has
been limited.14 16 Our results challenge a key criterion of all
previous recommendations—that is, the a priori specification
of the subgroup analysis. Given that in one out of three studies’
protocols do not corroborate reported claims of prespecification
of subgroup analyses, gains in credibility from this criterion are
limited.
The following steps could help to improve the trustworthiness
of reported subgroup analyses. Firstly, planned subgroup
analyses should be documented in trial registries. To date,
however, possibilities to enter such information in trial registries
are insufficiently developed. For example, there is a
non-mandatory “Group/Cohort” field in the registry
clinicaltrials.gov that could be used for subgroup
prespecification, but the corresponding data element description
remains unclear.23 The WHO International Clinical Trials
Registry platform24 and the registry Controlled Clinical Trials25
currently do not enable entry of information about subgroups.
Secondly, clinical investigators should adhere to guidelines for
protocols of randomised controlled trials such as the SPIRIT
statement.26 27 Research ethics committees and other review
boards should promote the use of such guidance documents.
Thirdly, journals should request access to protocols or statistical
analysis plans for their review process and make these
documents accessible to readers. In addition, journals could
enforce adherence to guidelines for the reporting of randomised
controlled trials (for example, the CONSORT statement)28 to
reduce the prevalent incomplete reporting of subgroup analyses.
Unless a reliable source such as a comprehensive trial protocol
is available, readers of trial reports should consider statements
about subgroup prespecifications with scepticism.When judging
the credibility of a subgroup effect, readers may look for similar
studies instead and consider whether subgroup findings are
consistent.
Conclusion
Large discrepancies exist between the planning and reporting
of subgroup analyses in randomised controlled trials. Published
statements about subgroup prespecification were not supported
by study protocols in about a third of cases. Our results highlight
the importance of enhancing the completeness and accuracy of
protocols of randomised controlled trials and their accessibility
to journal editors, reviewers, and readers.
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Tables
Table 1| Trial characteristics based on protocols. Values are numbers (percentages) unless stated otherwise
All trials (n=894)
Subgroup analyses
Characteristics Trials did plan (n=252)Trials did not plan (n=642)
260 (100-606)521 (229-1007)200 (80-460)Median (interquartile range) target sample size*
Centre status:
741 (82.9)241 (95.6)500 (77.9)Multicentre
149 (16.7)10 (4)139 (21.7)Single centre
4 (0.4)1 (0.4)3 (0.5)Unclear
Study design:
836 (93.5)244 (96.8)592 (92.2)Parallel
41 (4.6)1 (0.4)40 (6.2)Crossover
15 (1.7)6 (2.4)9 (1.4)Factorial
2 (0.2)1 (0.4)1 (0.2)Unclear
Study intention:
652 (72.9)196 (77.8)456 (71.0)Superiority
139 (15.5)44 (17.5)95 (14.8)Non-inferiority
103 (11.5)12 (4.8)91 (14.2)Unclear
Unit of randomisation:
879 (98.3)250 (99.2)629 (98.0)Individuals
12 (1.3)2 (0.8)10 (1.6)Clusters
3 (0.3)0 (0.0)3 (0.5)Body parts
Sponsorship:
343 (39.8)57 (22.6)286 (44.5)Investigator
551 (60.2)195 (77.4)356 (55.5)Industry
Clinical discipline:
155 (17.3)42 (16.7)113 (17.6)Oncology
108 (12.1)49 (19.4)59 (9.2)Cardiovascular
87 (9.7)27 (10.7)60 (9.3)Infectious disease
62 (6.9)15 (6.0)47 (7.3)Endocrinology
61 (6.8)24 (9.5)37 (5.8)Neurology
421 (47.1)95 (37.7)326 (50.8)Other
*Information missing in 12 protocols.
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Table 2| Subgroup credibility criteria based on trial protocols that planned at least one subgroup analysis. Values are numbers (percentages)
unless stated otherwise
All trials (n=252)
Sponsorship
Credibility criteria Investigator (n=57)Industry (n=195)
Clear hypothesis given?:
17 (6.7)10 (17.5)7 (3.6)Yes
235 (93.3)47 (82.5)188 (96.4)No
Direction of anticipated effect given?:
10 (4.0)7 (12.3)3 (1.5)Yes
242 (96.0)50 (87.7)192 (98.5)No
Interaction test planned?:
87 (34.5)18 (31.6)69 (35.4)Yes
165 (65.5)39 (68.4)126 (64.6)No
No of planned subgroup analyses:
3 (1, 4)3 (1, 6)3 (1, 6)Median (interquartile range)
30 (11.9)12 (21.1)18 (9.2)Not reported (No of studies)
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Table 3| Reported subgroup credibility criteria and interpretation of subgroup analyses based on publications that reported at least one
subgroup analysis. Values are numbers (percentages) unless stated otherwise
All trials (n=246)
Sponsorship
Reported credibility criteria and interpretation Investigator (n=86)Industry (n=160)
Prespecification of subgroup analyses reported in publication?:
81 (32.9)23 (26.7)58 (36.2)Yes
165 (67.1)63 (73.3)102 (63.7)No
Post hoc subgroup analyses reported in publication?:
48 (19.5)21 (24.4)27 (16.9)Yes
198 (80.5)65 (75.6)133 (83.1)No
Clear hypothesis given?:
21 (8.5)10 (11.6)11 (6.9)Yes
225 (91.5)76 (88.4)149 (93.1)No
Direction of anticipated effect given?:
11 (4.5)6 (7.0)5 (3.1)Yes
235 (95.5)80 (93.0)155 (96.9)No
Power calculation for subgroup analyses mentioned in publication?:
6 (2.4)3 (3.5)3 (1.9)Yes
240 (97.6)83 (96.5)157 (98.1)No
Test for interaction reported?:
96 (39.0)36 (41.9)60 (37.5)Yes
150 (61.0)50 (58.1)100 (62.5)No
No of reported subgroup analyses:
4 (2, 8)4 (2, 8)4 (1, 8)Median (interquartile range)
8 (3.3)2 (1.3)6 (3.8)Not reported
Any claim of subgroup effect reported?:
86 (35.0)29 (33.7)57 (35.6)Yes
160 (65.0)57 (66.3)103 (64.4)No
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Table 4| Agreement of planning and reporting of subgroup credibility criteria based on those 246 publications reporting at least one
subgroup analysis. Numbers are protocols/publications reporting or not reporting subgroup credibility criteria (percentages)
Reported in publicationPlanned in protocol
All trials (n=246)Investigator sponsorship (n=86)Industry sponsorship (n=160)
YesNoYesNoYesNoSubgroup hypothesis:
19 (7.7)216 (87.8)8 (9.3)73 (84.9)11 (6.9)143 (89.4)No
2 (0.8)9 (3.7)2 (2.3)3 (3.5)0 (0.0)6 (3.8)Yes
Direction of effect:
9 (3.7)231 (94.0)4 (4.7)78 (90.7)5 (3.1)153 (95.6)No
2 (0.8)4 (1.6)2 (2.3)2 (2.3)0 (0.0)2 (1.3)Yes
Interaction test:
72 (29.3)128 (52.0)26 (30.2)48 (55.8)46 (28.8)80 (50.0)No
24 (9.8)22 (8.9)10 (11.6)2 (2.3)14 (8.8)20 (12.5)Yes
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Figure
Study flow of protocols of randomised controlled trials and publications. *Only protocols from two subsidiary research ethics
committees responsible for paediatric and surgical randomised controlled trials were screened. †No results from randomised
comparison published
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